Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1986 1
1990 1
2004 1
2007 1
2008 3
2009 1
2010 4
2011 2
2012 5
2013 3
2014 7
2015 8
2016 5
2017 6
2018 3
2019 1
2020 4
2021 9
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

56 results
Results by year
Filters applied: . Clear all
Page 1
Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist.
Upadhyaya P, Lahdenranta J, Hurov K, Battula S, Dods R, Haines E, Kleyman M, Kristensson J, Kublin J, Lani R, Ma J, Mudd G, Repash E, Van Rietschoten K, Stephen T, You F, Harrison H, Chen L, McDonnell K, Brandish P, Keen N. Upadhyaya P, et al. Among authors: kristensson j. J Immunother Cancer. 2021 Jan;9(1):e001762. doi: 10.1136/jitc-2020-001762. J Immunother Cancer. 2021. PMID: 33500260 Free PMC article.
BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism.
Hurov K, Lahdenranta J, Upadhyaya P, Haines E, Cohen H, Repash E, Kanakia D, Ma J, Kristensson J, You F, Campbell C, Witty D, Kelly M, Blakemore S, Jeffrey P, McDonnell K, Brandish P, Keen N. Hurov K, et al. Among authors: kristensson j. J Immunother Cancer. 2021 Nov;9(11):e002883. doi: 10.1136/jitc-2021-002883. J Immunother Cancer. 2021. PMID: 34725211 Free PMC article.
56 results